Select Clinical Trial
Protocol Number: INSIGHT 013; NCT04546581
Protocol Title: An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19
Eligibility: Men and women age 18 and older requiring hospitalization for symptomatic COVID-19 disease.
Contact Information: (910) 715-220